Hydrogel formulation for administering non-steroidal drugs

• US 4,867,969 A
• Filed: 02/08/1988
• Issued: 09/19/1989
• Est. Priority Date: 02/07/1986
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Theeuwes, Felix, Guittard, George V., Magruder, Paul R., Wong, Patrick S.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): HORNE, LEON
• Application Number:
  US07/153,309
• Time in Patent Office: 589 Days
• Field of Search: 424/486, 424/422, 424/434, 424/438, 424/78
• US Class Current: 424/679
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50

Abstract

A composition of matter comprising a drug, a neutral hydrogel and an ionic hydrogel. The composition can be administered from a delivery system to a biological receptor over time.

Claims

1. A composition of matter for administering a beneficial drug to an animal, the composition comprising from 25 ng to 1.5 g of a beneficial drug and a blend comprising 1% to 60% polyethylene oxide and 1% to 60% potassium carboxyvinyl polymer.

2. A composition of matter for administering a beneficial drug to an animal, the composition comprising from 25 ng to 1.5 g of a beneficial drug and a blend comprising 1% to 60% polyethylene oxide and 1% to 60% sodium carboxyvinyl polymer.

3. A therapeutic composition for orally administering a drug to the gastrointestinal tract of an animal, said therapeutic composition comprising (1) from 25 ng to 1.5 g of a non-steroidal, anti-inflammatory analgesic that is a member selected from the group consisting of non-steroidal propionic, non-steroidal acetic, non-steroidal fenamic, non-steroidal biphenylcarboxylic, and non-steroidal oxicam drugs, (2) from 1% to 60% of a polyethylene oxide, and (3) from 1% to 60% of a carboxypolymethylene polymer, which (1), (2) and (3) are concomitantly administered to the gastrointestinal tract wherein (2) and (3) cooperate for reducing the concentration of (1) in contact with the gastrointestinal mucosa.